Rilpivirine With Darunavir/Ritonavir: Pharmacokinetics & Safety in HIV Therapy-Naïve Patients
Background: A combination of ritonavir-boosted darunavir (DRV/rtv) and rilpivirine (RPV) could potentially form a once-daily nucleoside-sparing regime for therapy-naive treatment. RPV is subject to the boosting effect of hepatic cytochrome inhibition, and in an interaction study in healthy volunteers DRV/rtv increased RPV pharmacokinetic (PK) exposures, of a RPV 150mg daily dose, by 80 to 180%without…